Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study identified a new genotype, V281+I172N/V281L, linked to non-classical 21-hydroxylase deficiency, suggesting it should be considered in genetic panels for the condition.

Finasteride reduces prostate cancer risk but may increase high-grade cancer cases.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.

This study concluded that androgenetic alopecia was not a prognostic indicator for COVID-19, but hospitalization frequency increased in older patients with benign prostatic hyperplasia, supporting an androgen-mediated severity hypothesis.

This study reports that comorbidities and anti-androgen therapy were associated with lower SARS-CoV-2 vaccination rates among patients with androgenetic alopecia, emphasizing the need to promote vaccination within this group.

This study observed no association between androgenetic alopecia and benign prostatic hyperplasia in men aged 20 and older, although a positive family history was linked to early onset of hair loss.

This study found no association between androgenetic alopecia and increased prostate volume or serum PSA levels in male patients aged 25–45.

This study found that patients with androgenetic alopecia frequently had higher PSA levels and more significant urinary symptoms, likely due to older age, though prostate weight did not differ.

Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.

Hair loss can be an early sign of prostate enlargement.

This study found that early-onset androgenetic alopecia is associated with higher prevalence of metabolic syndrome, atheroma plaques, and urinary symptoms related to prostate growth compared to controls.

Gene variation affects prostate issues and hair loss.

This study found that a basal 17-hydroxyprogesterone level is effective for screening nonclassic adrenal hyperplasia in women, with a 4 ng/mL cutoff providing high specificity and positive predictive value.

This review critically examines the current medical management strategies for BPH/LUTS and reports no new experimental results.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This review discusses the potential risks of ejaculatory dysfunction associated with both medical and surgical treatments for lower urinary tract symptoms due to benign prostatic hyperplasia and their implications for male fertility, but it reports no new clinical results.

This study found that overexpression of NSD3 in the mammary gland of transgenic mice led to mammary hyperplasia, dysplasia, and invasive ductal carcinoma, mirroring patterns seen in human breast cancer.

This review details contemporary medical management options for benign prostatic hyperplasia, highlighting the expanding role of phosphodiesterase-5 inhibitors and beta-3 agonists, but reports no new clinical findings.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This article updates on the medical management of benign prostatic hyperplasia in companion animals and reports no new clinical findings; the authors discuss existing treatments.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review discusses the use of finasteride for treating benign prostatic hyperplasia and highlights its potential for reducing prostate size, symptom control, and lowering the risk of surgery and urinary retention.

This study reports that a short course of steroids resolved symptoms and hyperplasia in infants and young children with recurrent intussusception associated with intestinal lymphoid hyperplasia, suggesting consideration of steroids before surgery.

Finasteride helps reduce prostate size and symptoms in BPH but is less effective than terazosin and works best for larger prostates.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.